Abstract
Epithelial ovarian cancer (EOC) is the fourth leading cause of cancer-related deaths in women in the United States and the leading cause of gynecologic cancer deaths. The major limiting factor in the treatment of ovarian cancer is recurrence and chemoresistance. Individuals who succumb to advancedstage ovarian cancer inevitably become refractory to chemotherapy, resulting in disease progression and death. The source of recurrence and lack of response to chemotherapy is unknown. The focus of this review is to evaluate the question of recurrence and chemoresistance based on the concept of the cancer stem cells and inflammation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 708-713 |
| Number of pages | 6 |
| Journal | Cancer Biology and Therapy |
| Volume | 11 |
| Issue number | 8 |
| DOIs | |
| State | Published - Apr 15 2011 |
Bibliographical note
Funding Information:These studies were supported in part by grants from NCI/NIH RO1CA127913, RO1CA118678, The Janet Burros Memorial Foundation, The Sands Family Foundation and the Discovery To Cure Research Program.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Inflammation
- Nuclear factor kappab
- Ovarian cancer
- Ovarian cancer stem cells
- Recurrence
- Toll-like receptors
Fingerprint
Dive into the research topics of 'Ovarian cancer stem cells and inflammation'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS